Literature DB >> 10384680

Quality of life assessment in the collaborative ocular melanoma study: design and methods. COMS-QOLS Report No. 1. COMS Quality of Life Study Group.

.   

Abstract

The Collaborative Ocular Melanoma Study (COMS) is a set of randomized clinical trials sponsored by the National Eye Institute of the National Institutes of Health. The COMS is being conducted to evaluate the role of radiotherapy in the treatment of patients with choroidal melanoma. Primary choroidal melanoma can enlarge or metastasize and eventually cause death in a significant percentage of cases. The primary COMS trial is designed to determine whether enucleation (removal of the eye) or radiotherapy without removal of the eye provides the patient with the longest remaining lifespan. More than 40 clinical centers in the United States and Canada are participating in the COMS. The objective of the COMS is to assess the effect of treatment upon 5-year and 10-year survival and the reduction or elimination of the disease process in patients randomly assigned to receive either radiation or enucleation. An ancillary component of the COMS, referred to as the COMS-QOLS, was designed to measure the impact of disease and its treatment on quality of life. The two treatment approaches being investigated, enucleation and radiation therapy, are likely to have different psychological and physiological effects on the patients receiving them. The COMS-QOLS assessments include the SF-36 Health Survey, the Activities of Daily Vision Scale (ADVS), the Visual Functioning Questionnaire (VFQ), and the Hospital Anxiety and Depression Scale (HADS). Patients are interviewed at selected intervals during follow-up; in addition, 200 patients will be interviewed before randomization and have repeat interviews at six months and annually after randomization. The patient's quality of life after treatment will become an important consideration in determining the best form of therapy, particularly in the event that no survival difference between treatment groups is found.

Entities:  

Mesh:

Year:  1999        PMID: 10384680     DOI: 10.1076/opep.6.1.5.1565

Source DB:  PubMed          Journal:  Ophthalmic Epidemiol        ISSN: 0928-6586            Impact factor:   1.648


  4 in total

1.  Comparison between patient-reported outcomes after enucleation and proton beam radiotherapy for uveal melanomas: a 2-year cohort study.

Authors:  Laura Hope-Stone; Stephen L Brown; Heinrich Heimann; Bertil Damato
Journal:  Eye (Lond)       Date:  2019-04-15       Impact factor: 3.775

2.  Quality of life in the follow-up of uveal melanoma patients after enucleation in comparison to CyberKnife treatment.

Authors:  A Klingenstein; C Fürweger; A K Mühlhofer; S F Leicht; U C Schaller; A Muacevic; B Wowra; C Hintschich; K H Eibl
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-11-16       Impact factor: 3.117

3.  Psychometric properties of the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25), Japanese version.

Authors:  Yoshimi Suzukamo; Tetsuro Oshika; Mitsuko Yuzawa; Yoshihiro Tokuda; Atsuo Tomidokoro; Kotaro Oki; Carol M Mangione; Joseph Green; Shunichi Fukuhara
Journal:  Health Qual Life Outcomes       Date:  2005-10-26       Impact factor: 3.186

Review 4.  Quality of Life, Depression, and Anxiety in Patients with Uveal Melanoma: A Review.

Authors:  Mario Miniati; Maria Grazia Fabrini; Federica Genovesi Ebert; Maricia Mancino; Alessandra Maglio; Gabriele Massimetti; Enrico Massimetti; Donatella Marazziti
Journal:  J Oncol       Date:  2018-03-20       Impact factor: 4.375

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.